Identification | More | [Name]
HS-173 | [CAS]
1276110-06-5 | [Synonyms]
HS-173 ethyl 6-(5-(phenylsulfonamido)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxylate 6-[5-[(Phenylsulfonyl)amino]-3-pyridinyl]imidazo[1,2-a]pyridine-3-carboxylic acid ethyl ester 6-[5-[(Phenylsulfonyl)amino]-3-pyridinyl]imidazo[1,2-a]pyridine-3-carboxylic acid ethyl ester HS-173 | [Molecular Formula]
C21H18N4O4S | [MDL Number]
MFCD28023584 | [MOL File]
1276110-06-5.mol | [Molecular Weight]
422.457 |
Chemical Properties | Back Directory | [Melting point ]
>193°C (dec.) | [density ]
1.38±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
Chloroform (Slightly), DMSO (Slightly) | [form ]
Solid | [pka]
6.84±0.40(Predicted) | [color ]
Grey to Brown |
Hazard Information | Back Directory | [Description]
HS-173 is an imidazopyridine analog that acts as a PI3Kα inhibitor with an IC50 value of 0.8 nM.1 It demonstrates antiproliferative activity in T47D, SK-BR-3, and MCF-7 cells with IC50 values of 0.6, 1.5, and 7.8 μM, respectively.1 HS-173 is reported to induce apoptosis by arresting the cell cycle at the G2/M phase and by activating caspases.2,3 It has also been shown to block VEGF-induced angiogenesis both in vitro and in vivo.2 | [Uses]
HS-173 is a potent PI3Kα inhibitor with anticancer activity. | [in vitro]
hs-173 inhibited the pi3k signaling pathway, and showed anti-proliferative effects on cancer cells. also, hs-173 induced cell cycle arrest at the g2/m phase and apoptosis. in addition, hs-173 decreased the expression hif-1a and vegf which play an important role in angiogenesis. this effect was confirmed by the suppression of tube formation and migration assay in vitro [1]. | [in vivo]
hs-173 diminished blood vessel formation in the matrigel plug assay in mice. these results suggest that hs-173 has potent anti-angiogenic activity in vivo [1]. | [target]
PI3Kα | [References]
[1] lee h, jung kh, jeong y, hong s, hong ss. hs-173, a novel phosphatidylinositol 3-kinase (pi3k) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis. cancer lett. 2013 jan 1;328(1):152-9. |
|
|